Renalytix AI plc Stock News

Enabling expertise in sales, population health and value-driven care models Enabling expertise in sales, population health and value-driven care models

Partnership marks a long-term commitment to reducing impact of kidney disease in large populations via integration of earlier risk assessment paired with comprehensive disease management Partnership m

NEW YORK, May 4, 2021 /PRNewswire/ -- Kantaro Biosciences, LLC, a joint venture between the Mount Sinai Health System and RenalytixAI (LSE: RENX) (NASDAQ: RNLX), announced today that COVID-SeroKlir,

Data from 1,325 CANVAS Participants with Baseline DKD Scored with KidneyIntelX Presented at International Society of Nephrology World Congress of Nephrology 2021 Data from 1,325 CANVAS Participants wi

Value of KidneyIntelX Testing Demonstrated by Data from 401 Physician Study Presented at National Kidney Foundation 2021 Spring Clinical Meetings Value of KidneyIntelX Testing Demonstrated by Data fro

Clinical findings published in the April issue of Diabetologia, the official journal of the European Association for the Study of Diabetes Clinical findings published in the April issue of Diabetolog

NEW YORK, March 04, 2021 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of

Innovative partnership to enable health system-wide approach to help delay or prevent progression in the earliest stages while advancing genetics research for detection, prognosis and treatment of chr

NEW YORK, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX) (“RenalytixAI” or the “Company”), the artificial intelligence-enabled in vitro diagnostics company, focu

Renalytix AI continues to soar. The story of AI-enhanced kidney diagnostics is attractive, albeit the addressable market isn't huge.

Creates Pathway for Beneficiary Access to KidneyIntelX for Medicare Beneficiary Kidney Disease Populations Creates Pathway for Beneficiary Access to KidneyIntelX for Medicare Beneficiary Kidney Diseas

Renalytix AI (RNLX) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

First-of-its-kind program combines early risk assessment of kidney decline and comprehensive care management to help slow kidney disease progression, improve care coordination and reduce costs First-o

NEW YORK, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of k

NEW YORK, Dec. 2, 2020 /PRNewswire/ --The National Kidney Foundation (NKF) announced today a partnership with Renalytix AI (NASDAQ:RNLX) to improve kidney disease diagnosis and assessment in the earli